Johnson & Johnson (JNJ) 104.10 $JNJ
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire Europe - Wed Jun 11, 12:44AM CDT
Jazz Pharmaceuticals plc today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Sabine Dandiguian Honoured as HBA Luminary by the Healthcare Businesswomen's Association (HBA)
PR Newswire Europe - Tue Jun 10, 10:13PM CDT
HAMBURG, Germany, May 13, 2014 /PRNewswire/ --
Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 5:45PM CDT
Pharmacyclics (PCYC) announced that the FDA will review its Imbruvica sNDA on a priority basis.
Final Glance: Medical Devices companies
AP - Tue Jun 10, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jun 10, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Dendreon's CEO Departs at Critical Juncture - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 4:20PM CDT
Dendreon (DNDN) is now faced with a difficult time with its chief executive officer John H. Johnson deciding to step down on personal reasons.
Dendreon's CEO Exits: Is this the Beginning of the End?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Dendreon CEO and Chairman John Johnson has decided to call it quits after overseeing the biotechnology company's turbulent restructuring and attempted turnaround over the last two years. In 2012, Johnson took over for Mitchell Gold, who was unable...
Midday Glance: Pharmaceuticals companies
AP - Tue Jun 10, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Jun 10, 12:20PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $103.59
Comtex SmarTrend(R) - Tue Jun 10, 10:41AM CDT
Johnson & Johnson (NYSE:JNJ) has opened bullishly above the pivot of $103.04 today and has reached the first level of resistance at $103.41. Analysts will be watching for a cross of the next upside pivot targets of $103.59 and $104.14.
Early Glance: Pharmaceuticals companies
AP - Tue Jun 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue Jun 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Mobitor Meets Customer Mobile Demands Faster With Ravello
Business Wire - Tue Jun 10, 8:00AM CDT
Ravello Systems, the industry's leading nested virtualization provider, today announced that Mobitor Corporation, a leader in mobile solutions that streamline field and backend operations, uses Ravello for agile development and test environments. Ravello's Software-as-a-Service (SaaS) solution enables Mobitor to clone its multi-tier on-premises production applications in any cloud without any modifications to the existing virtual machines or networking. Additionally, Ravello's built-in automation for full-stack provisioning enables developers and quality assurance (QA) teams to easily leverage the unlimited resources of the public cloud.
2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain
'Fast Money' Recap: Markets Start Another Week on Positive Note
at The Street - Tue Jun 10, 4:00AM CDT
The trading panel looked at the new post-split Apple and whether it's worth the investment.
Legal-Bay Lawsuit Settlement Funding Reports Finalization of $2.5 Billion Estimate in DePuy ASR Hip Settlements
PR Newswire - Tue Jun 10, 4:00AM CDT
Legal-Bay LLC, The Lawsuit Settlement Funding Company, disclosed today a new lawsuit cash advance program for clients with potential settlements in DePuy Orthopaedics Inc. litigations. In a late 2013 press release by parent company Johnson & Johnson and DePuy executives, the company stated "The U.S. settlement is valued at approximately $2.5 billion, based on an estimate of 8,000 patients participating in the program". The estimated 8,000 patients who filed against DePuy were facing ASR(TM) XL Acetabular Hip System or ASR(TM) Hip Resurfacing System complications and experienced pain, inflammation, infection to surrounding internal areas and tissue, and Metallosis. J&J, as well as the plaintiff's attorneys, have now announced that enough clients have opted-in for the settlement and that the settlement payments will be processed in the next few months.
Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis
Merck to pay $3.85B for hepatitis C drug developer
By LINDA A. JOHNSON - AP - Mon Jun 09, 4:37PM CDT
TRENTON, N.J. (AP) — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.
By End of 2018 the Global Protein Therapeutics Market is Estimated to Reach US$ 165 Billion as New Products Enter the Sector
M2 - Mon Jun 09, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3s8lj/global_protein) has announced the addition of the "Global Protein Therapeutics Market Outlook 2018" report to their offering. According to this new research report, Global Protein Therapeutics Market Outlook 2018, a large number of market players has been developing monoclonal antibodies (mAbs). This research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments. The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance. Companies Mentioned: - Abbott Laboratories - Amgen Inc. - Biogen Idec Inc. - Eli Lilly & Company - Johnson & Johnson - Merck Serono S.A. - Novo Nordisk - Pfizer - Roche Group - Sanofi-Aventis For more information visit http://www.researchandmarkets.com/research/c3...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Critical Alerts For Groupon, Baidu.com, Johnson and Johnson, First Solar, and Chipotle Mexican Grill Technology Released By InvestorsObserver
PR Newswire - Mon Jun 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GRPN, BIDU, JNJ, FSLR, and CMG.
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire Europe - Wed Jun 11, 12:44AM CDT
Jazz Pharmaceuticals plc today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Sabine Dandiguian Honoured as HBA Luminary by the Healthcare Businesswomen's Association (HBA)
PR Newswire Europe - Tue Jun 10, 10:13PM CDT
HAMBURG, Germany, May 13, 2014 /PRNewswire/ --
Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 5:45PM CDT
Pharmacyclics (PCYC) announced that the FDA will review its Imbruvica sNDA on a priority basis.
Final Glance: Medical Devices companies
AP - Tue Jun 10, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jun 10, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Dendreon's CEO Departs at Critical Juncture - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 4:20PM CDT
Dendreon (DNDN) is now faced with a difficult time with its chief executive officer John H. Johnson deciding to step down on personal reasons.
Dendreon's CEO Exits: Is this the Beginning of the End?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Dendreon CEO and Chairman John Johnson has decided to call it quits after overseeing the biotechnology company's turbulent restructuring and attempted turnaround over the last two years. In 2012, Johnson took over for Mitchell Gold, who was unable...
Midday Glance: Pharmaceuticals companies
AP - Tue Jun 10, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Jun 10, 12:20PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $103.59
Comtex SmarTrend(R) - Tue Jun 10, 10:41AM CDT
Johnson & Johnson (NYSE:JNJ) has opened bullishly above the pivot of $103.04 today and has reached the first level of resistance at $103.41. Analysts will be watching for a cross of the next upside pivot targets of $103.59 and $104.14.
Early Glance: Pharmaceuticals companies
AP - Tue Jun 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue Jun 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Mobitor Meets Customer Mobile Demands Faster With Ravello
Business Wire - Tue Jun 10, 8:00AM CDT
Ravello Systems, the industry's leading nested virtualization provider, today announced that Mobitor Corporation, a leader in mobile solutions that streamline field and backend operations, uses Ravello for agile development and test environments. Ravello's Software-as-a-Service (SaaS) solution enables Mobitor to clone its multi-tier on-premises production applications in any cloud without any modifications to the existing virtual machines or networking. Additionally, Ravello's built-in automation for full-stack provisioning enables developers and quality assurance (QA) teams to easily leverage the unlimited resources of the public cloud.
2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain
'Fast Money' Recap: Markets Start Another Week on Positive Note
at The Street - Tue Jun 10, 4:00AM CDT
The trading panel looked at the new post-split Apple and whether it's worth the investment.
Legal-Bay Lawsuit Settlement Funding Reports Finalization of $2.5 Billion Estimate in DePuy ASR Hip Settlements
PR Newswire - Tue Jun 10, 4:00AM CDT
Legal-Bay LLC, The Lawsuit Settlement Funding Company, disclosed today a new lawsuit cash advance program for clients with potential settlements in DePuy Orthopaedics Inc. litigations. In a late 2013 press release by parent company Johnson & Johnson and DePuy executives, the company stated "The U.S. settlement is valued at approximately $2.5 billion, based on an estimate of 8,000 patients participating in the program". The estimated 8,000 patients who filed against DePuy were facing ASR(TM) XL Acetabular Hip System or ASR(TM) Hip Resurfacing System complications and experienced pain, inflammation, infection to surrounding internal areas and tissue, and Metallosis. J&J, as well as the plaintiff's attorneys, have now announced that enough clients have opted-in for the settlement and that the settlement payments will be processed in the next few months.
Lupus Nephritis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fdzqtl/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Bristol-Myers Squibb Company - Baxter International Inc. - Johnson & Johnson - Biogen Idec Inc. - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Noxxon Pharma AG - Anthera Pharmaceuticals Inc. - Kadmon Pharmaceuticals, LLC - Azano Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/fd..._nephritis
Merck to pay $3.85B for hepatitis C drug developer
By LINDA A. JOHNSON - AP - Mon Jun 09, 4:37PM CDT
TRENTON, N.J. (AP) — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.
By End of 2018 the Global Protein Therapeutics Market is Estimated to Reach US$ 165 Billion as New Products Enter the Sector
M2 - Mon Jun 09, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c3s8lj/global_protein) has announced the addition of the "Global Protein Therapeutics Market Outlook 2018" report to their offering. According to this new research report, Global Protein Therapeutics Market Outlook 2018, a large number of market players has been developing monoclonal antibodies (mAbs). This research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments. The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance. Companies Mentioned: - Abbott Laboratories - Amgen Inc. - Biogen Idec Inc. - Eli Lilly & Company - Johnson & Johnson - Merck Serono S.A. - Novo Nordisk - Pfizer - Roche Group - Sanofi-Aventis For more information visit http://www.researchandmarkets.com/research/c3...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Critical Alerts For Groupon, Baidu.com, Johnson and Johnson, First Solar, and Chipotle Mexican Grill Technology Released By InvestorsObserver
PR Newswire - Mon Jun 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GRPN, BIDU, JNJ, FSLR, and CMG.
